GenEmbryomics is an early-stage Australian biotech developing a whole genome sequencing (WGS)-based preimplantation genetic testing (PGT) service for the IVF market. The company's sole product in development, Panacea-GenomeScreen, sequences the full genomes of both parents and an IVF embryo — a "trio analysis" — to screen for over 3,200 genetic conditions before implantation, including de novo mutations that conventional PGT methods cannot detect. GenEmbryomics sells testing services to IVF clinics at a fixed fee per report delivered; clinics then pass costs on to patients. The company operates an asset-light model with no internal lab, relying on third-party CLIA-certified labs for sequencing and running its proprietary bioinformatics pipeline on Illumina's cloud-based Emedgene platform. As of the filing date, GenEmbryomics has no revenue and has not commercially launched. Near-term growth hinges on converting a non-binding MoU with Progenesis — a U.S. PGT lab with an established IVF clinic network — into a binding distribution agreement. Beyond Panacea-GenomeScreen, the company has a pipeline of follow-on products including a pre-conception carrier screening test, an egg screening test, an embryo viability tool, and a blockchain-based genomic data sharing platform, all at early stages of development.